FTO inhibition drives MYC inhibition. The original CoH paper shows that Zan inhibits FTO which in turn influences MYC expression.
Prior preclinical models have shown Zantrene is functioning as a cardioprotective agent independently of FTO.
Unsure if that's the pathway, but I'd say not. A good way I like to think about it is if you turn a tree upside down - the trunk is cellular function as a whole, a main branch is FTO, and an offshoot from that main branch is MYC. You can't impact MYC without inhibiting FTO.
FTO inhibition drives MYC inhibition. The original CoH paper...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.045(2.80%) |
Mkt cap ! $260.3M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.55 | $94.33K | 60.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1250 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 5000 | 1 |
View Market Depth
| Last trade - 14.37pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.56 |
Change
-0.045 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.59 | $1.55 | 8174 | ||
| Last updated 14.21pm 16/05/2024 ? | |||||
| RAC (ASX) Chart |